← All indications
Lymphoma, Large B-Cell, Diffuse
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
Subtype terms (1)
More specific conditions that are subtypes of Lymphoma, Large B-Cell, Diffuse in the MeSH hierarchy.
- Plasmablastic Lymphoma
24 drugs (18 approved, 6 experimental)
Drugs by status
Approved for this indication (11)
Phase 4 trials (27)
- interferon beta-1b
- cytarabine
- ozanimod
- fingolimod
- methotrexate
- cyclophosphamide
- yangzhengxiaoji
- doxorubicin
- prednisone
- teriflunomide
- inactivated influenza vaccine
- ocrelizumab
- natalizumab
- idarubicin
- dimethyl fumarate
- lapatinib
- peginterferon beta-1a
- dexamethasone
- carboplatin
- vincristine
- epirubicin
- etoposide
- melphalan
- ifosfamide
- decitabine
- rituximab
- ofatumumab
Phase 3 trials (80)
- bebt-908
- avelumab
- cd19 car-t cells
- shr-a1912
- azacitidine
- vitamin d3
- ibritumomab tiuxetan
- chidamide
- brentuximab vedotin
- siponimod
- bortezomib
- cisplatin
- enzastaurin
- pneumococcal 13-valent conjugate vaccine
- methylprednisolone
- tocilizumab
- naproxen
- ibrutinib
- keyhole limpet hemocyanin
- Ripertamab
- thiotepa
- umbralisib
- nebivolol
- desloratadine
- bleomycin
- sirolimus
- gemcitabine
- cinobufacin
- lenalidomide
- zilovertamab vedotin
- +50 more
Phase 2 trials (207)
- onalespib
- tacrolimus
- vorinostat
- imo-8400
- pf-07901801
- hmpl-760
- gossypol
- tc-110 t cells
- ms-553
- navitoclax
- vistusertib
- avadomide
- entospletinib
- tq-b3525
- pomalidomide
- lansoprazole
- crg-022
- gen3009
- imc001
- opaganib
- durvalumab
- copanlisib
- bbt369
- cd19-car_lenti t cell
- stem cells
- tirelizumab
- ngr-htnf
- human papillomavirus 9-valent vaccine, recombinant
- imexon
- lag525
- +177 more
Phase 1 trials (142)
- 19-28z t cells
- syncar-001
- zm008
- in111-dota-biotin
- cd30-car t cells
- anti-cd19-car cmv-specific t-lymphocytes
- tetanus-cmv fusion peptide vaccine
- cc-97540
- sgn-tgt
- medi7247
- azd3965
- isotretinoin
- onm-501
- sgn-cd70a
- nx-2127
- clbr001
- spebrutinib
- telisotuzumab vedodin
- entinostat
- abbv-525
- belinostat
- sotrastaurin
- tanespimycin
- sasanlimab
- ly4152199
- apolizumab
- cd30.car-ebvst
- ro4929097
- sorafenib
- synkir-310
- +112 more
Other trials (23)
- ganoderma lucidum spore
- resca-rd06
- zr-dfo-rd06
- zr-dfo-r8b4
- ga-nota-r8b4
- umbilical cord mesenchymal stem cells
- foscarnet
- dendritic cell tumor fusion vaccine
- ganciclovir
- chia seed
- resca-r8b4
- interferon alpha-2b
- valganciclovir
- lentivirus vector rhiv7-shi-tar-ccr5rz-transduced hematopoietic progenitor cells
- lithium
- palifermin
- o6-benzylguanine
- [18f]rccb6
- zr-dfo-rb6
- ga-nota-rd06
- deferasirox
- autologous blood stem cells
- gallium citrate ga 67
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (106)
- ADC Therapeutics SARL
- AstraZeneca
- Amgen
- City of Hope National Medical Center
- Actoverco
- Chinese Anti-Cancer Association
- Pharmacyclics
- University of Modena and Reggio Emilia
- University of Lorraine
- Guangzhou Medical University
- Novartis
- Genmab
- Seattle Genetics
- Genentech
- U.O.A. di Ematologia Ospedale Molinette
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Charles University
- Roche
- Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
- Fujian Medical University
- ICON
- Catholic University of Korea
- Favrille
- The Lymphoma Academic Research Organisation
- University of Ulsan
- Tsinghua University
- Czech Lymphoma Study Group
- University of Washington
- Chonnam National University
- GlaxoSmithKline
- +76 more
Organization Involved with Phase 2 Indications (275)
- University of Oxford
- Chang Gung University
- Jerez Hospital
- Autolus Limited
- Technical University of Munich
- Zhejiang DTRM Biopharma
- University of London
- Institut Gustave Roussy
- Hospital Clinico Lozano Blesa
- National Institutes of Health (NIH)
- Case Western Reserve University
- Sevion Therapeutics
- Centaurus Biopharma Co., Ltd.
- University of Toronto
- University of Manchester
- University of Nebraska
- Medical City Children's Hospital, Dallas
- Hospital Dr. Jose Molina Orosa
- Icahn School of Medicine at Mount Sinai
- Osaka University
- Shijiazhuang Pharma Group (CSPC)
- Centre Leon Berard
- Thermo Fisher Scientific
- Immunomedics
- Son Llatzer Hospital
- National Marrow Donor Program
- Millennium Pharmaceuticals
- University of Cagliari
- Eli Lilly
- Shantou University
- +245 more
Organization Involved with Phase 1 Indications (51)
- NantWorks
- Celator Pharmaceuticals
- Sutro Biopharma
- Shanghai Celluar Biopharmaceutical Group Ltd.
- Thor Medical
- Austin Health
- GenScript
- Nanjing Bioheng Biotech Co., Ltd.
- National Comprehensive Cancer Network
- Wellington Zhaotai Therapies Limited
- Hrain Biotechnology Co., Ltd.
- St. Jude Children's Hospital
- Shanghai Cell Therapy Engineering Research Institute
- Washington University in St. Louis
- OHSU Knight Cancer Institute
- Saint John Regional Hospital
- Shattuck Labs
- Medical University of South Carolina
- Arno Therapeutics
- Triphase Research and Development Corporation
- Cellular Biomedicine Group Ltd.
- Teva
- OncoEthix
- Tennessee Oncology, PLLC
- Takeda
- Children's National Medical Center
- Otsuka
- miRagen Therapeutics, Inc.
- Olivia Newton-John Cancer Research Institute
- Celldex Therapeutics
- +21 more
Organization Involved with Other Experimental Indications (11)